Pancreatic Cancer Research

ResearcherPeking University First HospitalActive in the last 2 years

Lei Kang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8729-4547; OpenAlex author ID A5100389885. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers

Papers 4

  1. ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates. Co-author DOI 10.1007/s00259-025-07441-6↗
  2. Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.5c01223↗
  3. Pancreatic cancer detected with 18F-FDG PET/CT in a case of IgG4-related disease. Last author DOI 10.17235/reed.2023.9870/2023↗
  4. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Co-author DOI 10.1007/s00259-022-05954-y↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenpeng Huang · 4 shared papers, 2022–2025 · strength 0.91
  2. Xinyao Sun · 1 shared paper, 2025 · strength 0.26
  3. Tianyao Wang · 1 shared paper, 2025 · strength 0.26
  4. Weibo Cai · 1 shared paper, 2025 · strength 0.25
  5. Xu Yang · 1 shared paper, 2022 · strength 0.14
  6. Cuicui Li · 1 shared paper, 2022 · strength 0.14
  7. Jigang Yang · 1 shared paper, 2022 · strength 0.14
  8. Qingfang Miao · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.